{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:50:55Z","timestamp":1789941055321,"version":"4.0.1"},"reference-count":154,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":2177,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1194\/jlr.r051367","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T06:46:46Z","timestamp":1409035606000},"page":"2007-2021","source":"Crossref","is-referenced-by-count":79,"title":["Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review"],"prefix":"10.1016","volume":"55","author":[{"given":"C. Roger","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.M.","family":"Anantharamaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.R051367_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1503\/cmaj.070675","article-title":"The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials","volume":"178","author":"Josan","year":"2008","journal-title":"CMAJ."},{"key":"10.1194\/jlr.R051367_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCGENETICS.108.795013","article-title":"Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response","volume":"1","author":"Voora","year":"2008","journal-title":"Circ Cardiovasc Genet."},{"key":"10.1194\/jlr.R051367_bib4","doi-asserted-by":"crossref","first-page":"F680","DOI":"10.1152\/ajprenal.00209.2007","article-title":"Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells","volume":"293","author":"Chen","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1194\/jlr.R051367_bib5","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jacc.2011.11.064","article-title":"Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin\/kexin type 9","volume":"59","author":"Melone","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R051367_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02938395","article-title":"Residual risk in statin-treated patients: future therapeutic options","volume":"9","author":"Campbell","year":"2007","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1194\/jlr.R051367_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1194\/jlr.R051367_bib8","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archinte.1981.00340090024008","article-title":"Lipoproteins, cardiovascular disease, and death. The Framingham study","volume":"141","author":"Gordon","year":"1981","journal-title":"Arch. Intern. Med."},{"key":"10.1194\/jlr.R051367_bib9","first-page":"5A","article-title":"Cholesterol and lipids in the risk of coronary heart disease: the Framingham Heart Study","volume":"4","author":"Castelli","year":"1988","journal-title":"Can. J. Cardiol."},{"key":"10.1194\/jlr.R051367_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","article-title":"The role of HDL, ABCA1 and ABCG1 transporters in cholesterol efflux and immune responses","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCRESAHA.114.300935","article-title":"High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target","volume":"114","author":"L\u00fcscher","year":"2014","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.R051367_bib12","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1194\/jlr.R800058-JLR200","article-title":"Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall","volume":"50","author":"Getz","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib13","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2008.03.016","article-title":"Beyond high-density lipoprotein cholesterol levels. Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches","volume":"51","author":"deGoma","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R051367_bib14","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","article-title":"Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice","volume":"109","author":"Navab","year":"2004","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0033-0620(98)80010-8","article-title":"Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol","volume":"41","author":"Belalcazar","year":"1998","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1194\/jlr.R051367_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(86)90125-3","article-title":"Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects","volume":"35","author":"Gnasso","year":"1986","journal-title":"Metabolism."},{"key":"10.1194\/jlr.R051367_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1185\/030079903125001668","article-title":"Statin-fibrate combination: therapy for hyperlipidemia: a review","volume":"19","author":"Wierzbicki","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1194\/jlr.R051367_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11886-003-0109-x","article-title":"Niacin, lipids, and heart disease","volume":"5","author":"Malik","year":"2003","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1194\/jlr.R051367_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib20","doi-asserted-by":"crossref","first-page":"C58","DOI":"10.1016\/j.ehjsup.2004.04.002","article-title":"Are the effects of statins on HDL-cholesterol clinically relevant?","volume":"6","author":"Chapman","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R051367_bib21","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R051367_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R051367_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","article-title":"Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits","volume":"48","author":"Morehouse","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib24","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R051367_bib25","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R051367_bib26","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R051367_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-013-0071-8","article-title":"Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective","volume":"52","author":"Mohammadpour","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1194\/jlr.R051367_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0005-2795(70)90029-2","article-title":"Reassembly in vitro of a serum high density lipoprotein","volume":"207","author":"Hirz","year":"1970","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R051367_bib29","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1172\/JCI109956","article-title":"A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family","volume":"66","author":"Franceschini","year":"1980","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib30","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":"High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib31","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jacc.2007.12.010","volume":"51","author":"Parolini","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R051367_bib32","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/bi011716p","article-title":"Apolipoprotein A-IMilano and apolipoprotein A-IParis. exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I","volume":"41","author":"Bielicki","year":"2002","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R051367_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1074248411426144","article-title":"Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl\/6 mice","volume":"17","author":"Chen","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1194\/jlr.R051367_bib34","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","article-title":"Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux","volume":"33","author":"Diditchenko","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2013.10.018","article-title":"CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice","volume":"232","author":"Tardy","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","article-title":"Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans","volume":"100","author":"Eriksson","year":"1999","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib37","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R051367_bib38","doi-asserted-by":"crossref","unstructured":"TardifJ. C.BallantyneC. M.BarterP.DasseuxJ. L.FayadZ. A.GuertinM. C.KasteleinJ. J. P.KeyserlingC.KleppH.KoenigW..; for the Can HDL Infusions Significantly Quicken Atherosclerosis Regression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. Epub ahead of print. April 29, 2014; doi:10.1093\/eurheartj\/ehu171.","DOI":"10.1093\/eurheartj\/ehu171"},{"key":"10.1194\/jlr.R051367_bib39","doi-asserted-by":"crossref","unstructured":"TardifJ. C.Gr\u00e9goireJ.L'AllierP. L.IbrahimR.Lesp\u00e9ranceJ.HeinonenT. M.KouzS.BerryC.BasserR.LavoieM. A..; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA., 297: 1675\u20131682.","DOI":"10.1001\/jama.297.15.jpc70004"},{"issue":"suppl 1","key":"10.1194\/jlr.R051367_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht308.1947","article-title":"Infusion of CSL112, a novel formulation of human apolipoprotein A-I, in healthy subjects removes tissue cholesterol and directs its clearance","volume":"34","author":"Gille","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1194\/jlr.R051367_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcph.194","article-title":"A multiple ascending dose study of CSL112, an infused formulation of ApoA-I","volume":"54","author":"Easton","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1194\/jlr.R051367_bib42","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1529\/biophysj.106.085886","article-title":"A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis","volume":"91","author":"Rocco","year":"2006","journal-title":"Biophys. J."},{"key":"10.1194\/jlr.R051367_bib43","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1074\/jbc.271.11.5984","article-title":"Contrasting in vivo effects of murine and human apolipoprotein A-II: role of monomer versus dimer","volume":"271","author":"Gong","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-2275(20)33906-7","article-title":"Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet","volume":"39","author":"Escol\u00e0-Gil","year":"1998","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4093\/dmj.2012.36.1.56","article-title":"The association between apolipoprotein A-II and metabolic syndrome in Korean adults: a comparison study of apolipoprotein A-I and apolipoprotein B","volume":"36","author":"Yi","year":"2012","journal-title":"Diabetes Metab. J."},{"key":"10.1194\/jlr.R051367_bib46","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA."},{"key":"10.1194\/jlr.R051367_bib47","doi-asserted-by":"crossref","first-page":"10256","DOI":"10.1016\/S0021-9258(17)39239-6","article-title":"Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function","volume":"260","author":"Chung","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-5793(74)80064-5","article-title":"A molecular theory of lipid-protein interactions in the plasma lipoproteins","volume":"38","author":"Segrest","year":"1974","journal-title":"FEBS Lett."},{"key":"10.1194\/jlr.R051367_bib49","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0065-3233(08)60643-9","article-title":"The amphipathic \u03b1 helix: A multifunctional structural motif in plasma apolipoproteins","volume":"45","author":"Segrest","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1194\/jlr.R051367_bib50","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1016\/S0021-9258(20)79708-5","article-title":"The mechanism of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I and an amphiphilic peptide","volume":"255","author":"Yokoyama","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib51","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1021\/bi00317a036","article-title":"In vitro binding of synthetic acylated lipid-associating peptides to high-density lipoproteins: effect of hydrophobicity","volume":"23","author":"Ponsin","year":"1984","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R051367_bib52","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1016\/S0021-9258(17)39238-4","article-title":"Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine","volume":"260","author":"Anantharamaiah","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib53","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1172\/JCI117515","article-title":"Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol","volume":"94","author":"Mendez","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib54","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.1016\/S0021-9258(18)48092-1","article-title":"Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation","volume":"262","author":"Epand","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1194\/jlr.M500240-JLR200","article-title":"Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1","volume":"47","author":"Tang","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib56","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-2275(20)31599-6","article-title":"Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide","volume":"42","author":"Datta","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib57","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0076-6879(86)28092-1","article-title":"Reconstitution of high-density lipoproteins","volume":"128","author":"Jonas","year":"1986","journal-title":"Methods Enzymol."},{"key":"10.1194\/jlr.R051367_bib58","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-2275(20)31163-9","article-title":"A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis","volume":"42","author":"Garber","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/01.ATV.10.1.95","article-title":"Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-I","volume":"10","author":"Anantharamaiah","year":"1990","journal-title":"Arteriosclerosis."},{"key":"10.1194\/jlr.R051367_bib60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/01.RES.0000181229.69508.2f","article-title":"Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice","volume":"97","author":"Navab","year":"2005","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.R051367_bib61","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1161\/01.ATV.0000174589.70190.e2","article-title":"An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice","volume":"25","author":"Navab","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib62","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1194\/jlr.M900151-JLR200","article-title":"An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide","volume":"50","author":"Wool","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib63","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1194\/jlr.M200475-JLR200","article-title":"Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway","volume":"44","author":"Remaley","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib64","doi-asserted-by":"crossref","first-page":"e68802","DOI":"10.1371\/journal.pone.0068802","article-title":"An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice","volume":"8","author":"Ditiatkovski","year":"2013","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R051367_bib65","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1194\/jlr.M003665","article-title":"A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice","volume":"51","author":"Bielicki","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib66","doi-asserted-by":"crossref","first-page":"13414","DOI":"10.1021\/ja404714a","article-title":"Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs","volume":"135","author":"Zhao","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1194\/jlr.R051367_bib67","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/01.ATV.16.2.328","article-title":"Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly","volume":"16","author":"Palgunachari","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib68","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1194\/jlr.M800075-JLR200","article-title":"Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I","volume":"49","author":"Van Lenten","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib69","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.CIR.0000070589.61860.A9","article-title":"L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease","volume":"107","author":"Ou","year":"2003","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib70","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1194\/jlr.M800046-JLR200","article-title":"L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice","volume":"49","author":"Peterson","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib71","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/jcb.23188","article-title":"Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice","volume":"112","author":"Vecoli","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1194\/jlr.R051367_bib72","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.2337\/db10-0844","article-title":"Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes","volume":"59","author":"Morgantini","year":"2010","journal-title":"Diabetes."},{"key":"10.1194\/jlr.R051367_bib73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1620\/tjem.220.223","article-title":"D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1","volume":"220","author":"Xie","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1194\/jlr.R051367_bib74","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/01.ATV.12.8.886","article-title":"Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties","volume":"12","author":"Garber","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1194\/jlr.R051367_bib75","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib76","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1194\/jlr.M700138-JLR200","article-title":"Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits","volume":"48","author":"Van Lenten","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib77","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","article-title":"Inflammatory\/anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment","volume":"108","author":"Ansell","year":"2003","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib78","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1096\/fj.10-165670","article-title":"4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice","volume":"25","author":"Wool","year":"2011","journal-title":"FASEB J."},{"key":"10.1194\/jlr.R051367_bib79","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/01.ATV.0000167412.98221.1a","article-title":"D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice","volume":"25","author":"Navab","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib80","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1194\/jlr.M013144","article-title":"Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally","volume":"52","author":"Navab","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib81","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1194\/jlr.M033555","article-title":"A novel approach to oral apoA-I mimetic therapy","volume":"54","author":"Chattopadhyay","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib82","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1194\/jlr.M042051","article-title":"Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid","volume":"54","author":"Navab","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib83","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1124\/jpet.107.129411","article-title":"Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides","volume":"324","author":"Gomaraschi","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1194\/jlr.R051367_bib84","doi-asserted-by":"crossref","first-page":"32273","DOI":"10.1074\/jbc.M804461200","article-title":"Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides","volume":"283","author":"Sethi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib85","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/ATVBAHA.109.200196","article-title":"The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro","volume":"30","author":"Tabet","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4049\/jimmunol.1001534","article-title":"5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma","volume":"186","author":"Yao","year":"2011","journal-title":"J. Immunol."},{"key":"10.1194\/jlr.R051367_bib87","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCRESAHA.110.216507","article-title":"Structure\/function relationships of apolipoprotein A-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein","volume":"107","author":"D'Souza","year":"2010","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.R051367_bib88","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1074\/jbc.270.4.1602","article-title":"Effect of the arrangement of tandem repeating units of class A amphipathic alpha-helixes on lipid interaction","volume":"270","author":"Mishra","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib89","doi-asserted-by":"crossref","unstructured":"ZhaoY.BlackA. S.BonnetD. J.MaryanoffB. E.CurtissL. K.LemanL. J.GhadiriM.R.. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J. Lipid Res. Epub ahead of print. June 29, 2014; doi:10.1194\/jlr.M049262.","DOI":"10.1194\/jlr.M049262"},{"key":"10.1194\/jlr.R051367_bib90","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","article-title":"Safety, pharmacokinetics and pharmacodynamics of a single dose of oral apolipoprotein A-I mimetic peptide D-4F in high-risk cardiovascular patients","volume":"49","author":"Bloedon","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1194\/jlr.M011098","article-title":"Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function","volume":"52","author":"Watson","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib92","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbalip.2013.10.012","article-title":"Searching for a successful HDL-based treatment strategy","volume":"1841","author":"Reddy","year":"2014","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R051367_bib93","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/bi991209w","article-title":"The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts","volume":"39","author":"Datta","year":"2000","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R051367_bib94","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1194\/jlr.M200157-JLR200","article-title":"Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization","volume":"43","author":"Segall","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib95","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1172\/JCI67398","article-title":"Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans","volume":"123","author":"Gonzales","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib96","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1073\/pnas.95.13.7585","article-title":"Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma","volume":"95","author":"Zhu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R051367_bib97","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1126\/science.7863332","article-title":"Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation","volume":"267","author":"Linton","year":"1995","journal-title":"Science."},{"key":"10.1194\/jlr.R051367_bib98","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/01.ATV.0000154570.50696.2c","article-title":"Apolipoprotein E and atherosclerosis-beyond lipid effect","volume":"25","author":"Davignon","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib99","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/ATVBAHA.111.238964","article-title":"ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory monocytes on monocytes and vascular endothelium","volume":"32","author":"Gaudreault","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib100","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/01.RES.0000187467.67684.43","article-title":"Apolipoprotein E suppresses the type I inflammatory response in vivo","volume":"97","author":"Ali","year":"2005","journal-title":"Circ. Res."},{"key":"10.1194\/jlr.R051367_bib101","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.1074\/jbc.M009915200","article-title":"Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality","volume":"276","author":"Van Oosten","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib102","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-2362.2000.00715.x","article-title":"Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae","volume":"30","author":"de Bont","year":"2000","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib103","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0310057X0903700111","article-title":"APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy","volume":"37","author":"Wang","year":"2009","journal-title":"Anaesth. Intensive Care."},{"key":"10.1194\/jlr.R051367_bib104","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/01.CCM.0000186368.96146.FB","article-title":"APOE polymorphism is associated with risk of severe sepsis in surgical patients","volume":"33","author":"Moretti","year":"2005","journal-title":"Crit. Care Med."},{"key":"10.1194\/jlr.R051367_bib105","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S0022-2275(20)32160-X","article-title":"Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo","volume":"39","author":"Roselaar","year":"1998","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib106","doi-asserted-by":"crossref","first-page":"12040","DOI":"10.1073\/pnas.90.24.12040","article-title":"In vivo protection against endotoxin by plasma high density lipoprotein","volume":"90","author":"Levine","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R051367_bib107","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1161\/01.CIR.99.19.2571","article-title":"Retroviral gene therapy in apoE-deficient mice: apoE expression in the artery wall reduces early foam cell lesion formation","volume":"99","author":"Hasty","year":"1999","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib108","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00041433-200006000-00004","article-title":"Apolipoprotein E and atherosclerosis","volume":"11","author":"Curtiss","year":"2000","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R051367_bib109","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1172\/JCI117687","article-title":"Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall","volume":"95","author":"Shimano","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib110","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI118271","article-title":"Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice","volume":"96","author":"Bellosta","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib111","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/ATVBAHA.111.222745","article-title":"Apolipoprotein E induces anti-inflammatory phenotype in macrophages","volume":"31","author":"Baitsch","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib112","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1073\/pnas.94.9.4647","article-title":"Increased atherosclerosis in C57BL\/6 mice reconstituted with apolipoprotein E null macrophages","volume":"94","author":"Fazio","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R051367_bib113","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1172\/JCI43802","article-title":"Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of ApoE\u2212\/\u2212 mice during disease regression","volume":"121","author":"Potteaux","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib114","doi-asserted-by":"crossref","first-page":"e80441","DOI":"10.1371\/journal.pone.0080441","article-title":"Leukocytosis and enhanced susceptibility to endotoxemia but not atherosclerosis in adrenalectomized apoE knockout mice","volume":"8","author":"Hoekstra","year":"2013","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R051367_bib115","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1172\/JCI57559","article-title":"ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice","volume":"121","author":"Murphy","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosis.2013.03.031","article-title":"Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children","volume":"229","author":"Tolani","year":"2013","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib117","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1161\/ATVBAHA.112.300134","article-title":"Cholesterol efflux a novel regulator of myelopoiesis and atherogenesis","volume":"32","author":"Tall","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib118","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbalip.2011.08.003","article-title":"Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells","volume":"1821","author":"Murphy","year":"2012","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R051367_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science."},{"key":"10.1194\/jlr.R051367_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-2275(20)33334-4","article-title":"Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E","volume":"40","author":"Mahley","year":"1999","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib121","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11594190-000000000-00000","article-title":"Apolipoprotein E mimetics and cholesterol-lowering properties","volume":"11","author":"Sharifov","year":"2011","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1194\/jlr.R051367_bib122","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-2275(20)31620-5","article-title":"Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo","volume":"42","author":"Datta","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib123","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-2275(20)39756-X","article-title":"Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor","volume":"36","author":"Dyer","year":"1995","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib124","doi-asserted-by":"crossref","first-page":"11142","DOI":"10.1021\/bi00035a020","article-title":"Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity","volume":"34","author":"Clay","year":"1995","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R051367_bib125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1172\/JCI1099","article-title":"An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo","volume":"101","author":"Nikoulin","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1194\/jlr.R051367_bib126","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1021\/bi602407r","article-title":"The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins","volume":"46","author":"Vedhachalam","year":"2007","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R051367_bib127","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1021\/bi2002955","article-title":"HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution","volume":"50","author":"Zheng","year":"2011","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R051367_bib128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.106.103671","article-title":"Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis","volume":"318","author":"Li","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1194\/jlr.R051367_bib129","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1089\/neu.2006.0192","article-title":"COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury","volume":"24","author":"Laskowitz","year":"2007","journal-title":"J. Neurotrauma."},{"key":"10.1194\/jlr.R051367_bib130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuropharm.2008.05.016","article-title":"N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein","volume":"55","author":"Sheng","year":"2008","journal-title":"Neuropharmacology."},{"key":"10.1194\/jlr.R051367_bib131","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2009.07.019","article-title":"Anti-inflammatory properties and recycling of Ac-hE18a-NH2: implications in the inhibition of atherosclerosis","volume":"208","author":"Datta","year":"2010","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib132","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1161\/CIRCULATIONAHA.104.497107","article-title":"An apolipoprotein E mimetic peptide dramatically lowers atherogenic lipoproteins and restores endothelial function in Watanabe heritable hyperlipidemic rabbits","volume":"111","author":"Gupta","year":"2005","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib133","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2012.10.064","article-title":"Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice","volume":"227","author":"Handattu","year":"2013","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib134","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(03)00101-1","article-title":"Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice","volume":"168","author":"Garber","year":"2003","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib135","first-page":"A10759","article-title":"Sustained effects of apolipoprotein E mimetic peptides on established atherosclerotic lesions in apo E null mice","volume":"128","author":"Goldberg","year":"2013","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-60761-350-3_1","article-title":"ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity","volume":"660","author":"Datta","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1194\/jlr.R051367_bib137","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JAD-122377","article-title":"In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-\u03b2 pathology","volume":"36","author":"Handattu","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1194\/jlr.R051367_bib138","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/01.ATV.0000152613.83243.12","article-title":"Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels","volume":"25","author":"Raffai","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1194\/jlr.R051367_bib139","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2012.09.018","article-title":"Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening","volume":"2","author":"Kothapalli","year":"2012","journal-title":"Cell Reports."},{"key":"10.1194\/jlr.R051367_bib140","doi-asserted-by":"crossref","first-page":"D526","DOI":"10.2741\/Swertfeg","article-title":"Apolipoprotein E: A cholesterol transport protein with lipid transport-independent cell signaling properties","volume":"6","author":"Swertfeger","year":"2001","journal-title":"Front. Biosci."},{"key":"10.1194\/jlr.R051367_bib141","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.atherosclerosis.2012.05.040","article-title":"Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice","volume":"224","author":"Nayyar","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib142","doi-asserted-by":"crossref","unstructured":"SharifovO. F.NayyarG.TernovoyV. V.PalgunachariM. N.GarberD. W.AnantharamaiahG.GuptaH.. Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A. Innate Immun. Epub ahead of print. Dec 9, 2013; doi:10.1177\/1753425913514621.","DOI":"10.1177\/1753425913514621"},{"key":"10.1194\/jlr.R051367_bib143","doi-asserted-by":"crossref","first-page":"22112","DOI":"10.1016\/S0021-9258(20)80655-3","article-title":"Reciprocal effects of apolipoprotein and lytic peptide analogs on membranes. Cross- sectional molecular shapes of amphipathic alpha-helixes control membrane stability","volume":"268","author":"Tytler","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R051367_bib144","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1194\/jlr.M006916","article-title":"Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice","volume":"51","author":"Handattu","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib145","doi-asserted-by":"crossref","unstructured":"WoolG.ReardonC. A.GetzG. S.. Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?, J. Lipid Res. Epub ahead of print. August 1, 2014; doi:10.1194\/jlr.E053538.","DOI":"10.1194\/jlr.E053538"},{"key":"10.1194\/jlr.R051367_bib146","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1\u03b1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R051367_bib147","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1194\/jlr.R051367_bib148","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R051367_bib149","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOL.0b013e3283613a3d","article-title":"PCSK9 inhibitors","volume":"24","author":"Farnier","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1194\/jlr.R051367_bib150","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1194\/jlr.R051367_bib151","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation."},{"key":"10.1194\/jlr.R051367_bib152","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacl.2010.08.013","article-title":"Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis","volume":"4","author":"Hemphill","year":"2010","journal-title":"J. Clin. Lipidol."},{"key":"10.1194\/jlr.R051367_bib153","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1194\/jlr.R051367_bib154","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1194\/jlr.M048348","article-title":"apoE3[K146N\/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL","volume":"55","author":"Fotakis","year":"2014","journal-title":"J. Lipid Res."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520350057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520350057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.R051367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T18:43:19Z","timestamp":1637433799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520350057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0022227520350057"],"URL":"https:\/\/doi.org\/10.1194\/jlr.r051367","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}